June 13, 2024 03:46 PM EDT

Bristol Myers' cancer drug Augtyro wins new accelerated approval in solid tumors

Bristol Myers Squibb’s 2022 buyout of Turning Point Therapeutics for $4.1 billion continues to score wins at the FDA.

On Thursday,

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bris­tol My­er­s' can­cer drug Aug­ty­ro wins new ac­cel­er­at­ed ap­proval in sol­id tu­mors